Business Wire

PA-PMI

8.2.2021 20:06:03 CET | Business Wire | Press release

Share
Project Management Institute’s Megatrends 2021 Underscores How Projects Will Counterbalance the Rising Forces of Disruption

Project Management Institute (PMI) has released its latest report on long-term business, geopolitical, and technological trends that are reshaping our world and the types of projects that will be most prevalent and critical in the years to come in the face of these disruptions. Megatrends 2021 helps to ensure that project leaders can better understand the world’s rapid transformation and the global context in which they are working today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005744/en/

“We know the world changed significantly in 2020, but our research confirmed the long-term impact of how these trends are changing how the world does business,” said Sunil Prashara, President and CEO of Project Management Institute. “There is virtually no industry and no geography that is untouched by the five megatrends outlined in this report. From COVID-19 to the climate crisis to the mainstream use of AI, these forces are driving change across sectors, requiring leaders to embrace new ways of thinking and working. As change-makers in their organizations and communities, project leaders are in a unique position to tackle these challenges and embrace new possibilities.”

The report, which draws on trend data, secondary research, and interviews with project professionals, news reports, and industry data, elaborates on a range of cross-cutting and urgent themes:

  • The impact of COVID-19 revealed deep vulnerabilities in our technology preparedness capabilities and deep-seated inequities in our health, education, and economic systems.
  • The climate crisis is compelling leaders in every sector to collaborate and marshal resources on a global scale to alter the broad trajectory of climate change and mitigate its many near-term consequences.
  • The global wave of protests spanning the past decade has revealed that change is not a question of if, but rather when, and has sparked a growing corporate commitment to racial, gender and ethnic diversity.
  • Emerging markets hold the promise of addressing long-festering challenges like global poverty, as well as the potential to reap the demographic dividend, but still require significant global investments in infrastructure and education.
  • The growth of artificial intelligence (AI) has rewired the possibilities for technology and continued learning, but leaders must grapple with the ethical implications of AI on the complex issues of bias and inequality.

These complex challenges will continue to drive demand for versatile and bold project talent who can help make social impact projects a strategic priority, foster open and innovative partnership ecosystems, and rethink relationships with customers and wider stakeholders.

Project-based skills are essential to helping enterprises turn ideas into a reality. The capabilities of project professionals and change-makers with a broad global perspective will only grow in The Project Economy , the emerging global landscape in which organizations will increasingly deliver financial and societal value through the successful completion of projects, delivery of products, and alignment to value streams.

“We live in a world of change and uncertainty—and COVID-19 has accelerated these trends with major shocks and disruptions to the world of business and society itself overnight,” said Prashara. “This report provides a preview of the world we’ll live in and how our community of project professionals and change-makers can drive greater social impact and value, no matter what sector or corner of the world. Success today requires that they continue to cultivate a strong business acumen and understanding of the broader strategic environment in which we’re operating.”

You can read the full Megatrends 2021 report online at https://www.pmi.org/learning/thought-leadership/megatrends .

About Project Management Institute (PMI)

Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® interactive website creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye